These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34972972)

  • 1. Immunotherapy-Mediated Luminal Gastrointestinal Toxicities.
    Thomas AS; Wang Y
    Adv Exp Med Biol; 2021; 1342():331-337. PubMed ID: 34972972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-related luminal GI adverse events.
    Kröner PT; Mody K; Farraye FA
    Gastrointest Endosc; 2019 Dec; 90(6):881-892. PubMed ID: 31526811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal Tract Adverse Events.
    Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
    Cramer P; Bresalier RS
    Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
    Dougan M
    Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors.
    Townsend MJ; Benque IJ; Li M; Grover S
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1350-1365. PubMed ID: 38590108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
    J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
    Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
    J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
    Klein BA; Alves FA; de Santana Rodrigues Velho J; Vacharotayangul P; Hanna GJ; LeBoeuf NR; Shazib MA; Villa A; Woo SB; Sroussi H; Sonis S; Treister NS
    Oral Dis; 2022 Jan; 28(1):9-22. PubMed ID: 34265157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurologic Toxicities of Immunotherapy.
    Harrison RA; Majd NK; Tummala S; de Groot JF
    Adv Exp Med Biol; 2021; 1342():417-429. PubMed ID: 34972978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors-Induced Colitis.
    Tian Y; Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological toxicities associated with immune-checkpoint inhibitors.
    Touat M; Talmasov D; Ricard D; Psimaras D
    Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition and management of the gastrointestinal and hepatic immune-related adverse events.
    Tan B; Li Y; Xu Y; Chen M; Wang M; Qian J
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):95-102. PubMed ID: 32077625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy.
    Rajha E; Chaftari P; Kamal M; Maamari J; Chaftari C; Yeung SJ
    Gastroenterol Rep (Oxf); 2020 Feb; 8(1):25-30. PubMed ID: 32104583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
    Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
    Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
    Fessas P; Possamai LA; Clark J; Daniels E; Gudd C; Mullish BH; Alexander JL; Pinato DJ
    Immunology; 2020 Feb; 159(2):167-177. PubMed ID: 31646612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.